Second Generation Antipsychotics Market, By Indication, By Drug Class, By Route of Administration, By Distribution Channel, By Geography

Description

Global Second Generation Antipsychotics Market is estimated to be valued at USD 10.25 Bn in 2025 and is expected to reach USD 15.67 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.25% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 10.25 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	6.25%	2032 Value Projection:	USD 15.67 Bn

The global second generation antipsychotics market has witnessed significant growth in recent years, driven by the increasing prevalence of mental health disorders and the rising demand for effective treatments. Second generation antipsychotics, also known as atypical antipsychotics, have emerged as a preferred choice for the management of various psychiatric conditions, including schizophrenia, bipolar disorder, and major depressive disorder. These medications offer several advantages over first generation antipsychotics, such as improved efficacy, reduced extrapyramidal side effects, and better tolerability. The market for second generation antipsychotics is expected to continue its upward trajectory, fueled by the growing awareness about mental health, the development of novel formulations, and the expanding indications for these drugs.

Market Dynamic:

The global second generation antipsychotics market is driven by several factors, including the growing geriatric population, and the increasing awareness about mental health. The World Health Organization estimates that around 450 million people globally suffer from mental health disorders, creating a significant demand for effective treatments. Additionally, the development of long-acting injectable formulations of second generation antipsychotics has improved patient compliance and convenience, further driving market growth. However, the market also faces certain restraints, such as the high cost of these medications, the potential for side effects, and the stigma associated with mental health disorders. Patent expiration of key drugs and the emergence of generic alternatives may also impact the market dynamics. Nevertheless, the market presents substantial opportunities for growth, driven by the increasing focus on personalized medicine, the development of novel drug delivery systems, and the expanding applications of second generation antipsychotics in the treatment of other psychiatric disorders.

Key Features of the Study:

This report provides in-depth analysis of the global second generation antipsychotics market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global second generation antipsychotics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Johnson & Johnson, Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb, Pfizer, Novartis, Otsuka Pharmaceutical, Lundbeck, Sanofi, Merck & Co., AbbVie, Takeda Pharmaceutical, Amgen, GlaxoSmithKline, and Alkermes
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global second generation antipsychotics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global second generation antipsychotics market

Market Segmentation

Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Schizophrenia
- Bipolar Disorder
- Major Depressive Disorder
- Autism Spectrum Disorder
- Other Indications
Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- Risperidone
- Quetiapine
- Olanzapine
- Aripiprazole
- Asenapine
- Clozapine
- Paliperidone
- Brexpiprazole
- Lurasidone
- Others
Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Parenteral
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Johnson & Johnson
- Eli Lilly and Company
- AstraZeneca
- Bristol-Myers Squibb
- Pfizer
- Novartis
- Otsuka Pharmaceutical
- Lundbeck
- Sanofi
- Merck & Co.
- AbbVie
- Takeda Pharmaceutical
- Amgen
- GlaxoSmithKline
- Alkermes

Product Code: CMI7888

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Second Generation Antipsychotics Market, By Indication
- Global Second Generation Antipsychotics Market, By Drug Class
- Global Second Generation Antipsychotics Market, By Route of Administration
- Global Second Generation Antipsychotics Market, By Distribution Channel
- Global Second Generation Antipsychotics Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Driver
- Restraint
- Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Second Generation Antipsychotics Market, By Indication, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Schizophrenia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Bipolar Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Major Depressive Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Autism Spectrum Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Other Indications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Second Generation Antipsychotics Market, By Drug Class, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Risperidone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Quetiapine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Olanzapine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Aripiprazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Asenapine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Clozapine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Paliperidone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Brexpiprazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Lurasidone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Second Generation Antipsychotics Market, By Route of Administration, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Second Generation Antipsychotics Market, By Distribution Channel, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Second Generation Antipsychotics Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

9. Competitive Landscape

Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Otsuka Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Lundbeck
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Takeda Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Alkermes
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies

10. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

11. References and Research Methodology

References
Research Methodology
About us